Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 25, 2015 7:02 AM ET

Pharmaceuticals

Company Overview of AstraZeneca AB

Company Overview

AstraZeneca AB offers research, development, manufacture, and marketing of pharmaceutical products for gastrointestinal, cardiovascular, respiratory, and pain control.. The company was formerly known as Astra AB and changed its name to AstraZeneca AB in April 1999. The company was founded in 1913 and is based in Sodertalje, Sweden. AstraZeneca AB operates as a subsidiary of AstraZeneca PLC.

Karlebyhus

Astraallén

Sodertalje,  151 85

Sweden

Founded in 1913

24,958 Employees

Phone:

46 8 55 32 60 00

Fax:

46 8 55 32 90 00

Key Executives for AstraZeneca AB

President
Head of Production
Other Professional
Compensation as of Fiscal Year 2014.

AstraZeneca AB Key Developments

Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study

Dynavax Technologies Corp. announced that the Company and AstraZeneca AB (AstraZeneca) signed an amendment to the existing Research Collaboration and License Agreement under which AstraZeneca will fully fund and Dynavax will conduct a Phase 2a safety and efficacy trial of AZD1419 in patients with asthma. AZD1419 is a proprietary, second-generation TLR9 agonist CpG oligodeoxynucleotide formulated for inhalation use. The decision to accelerate this potential disease-modifying therapeutic into Phase 2, eliminating the previously planned Phase 1b study, was based on the positive results of a Phase 1a study in 45 healthy volunteers. The primary study objective was assessment of the safety of 4 weekly doses of AZD1419 or placebo. Ascending doses were well tolerated with no serious adverse events observed in treated subjects. Additional endpoints assessing pharmacodynamics were met, with dose-dependent induction of interferon-regulated genes in sputum and blood cells. Dynavax intends to initiate the Phase 2a study in asthma patients in the first half of 2015 and a milestone is payable on its initiation. Remaining potential milestone payments to Dynavax total approximately $100 million. In addition, Dynavax will receive royalties on worldwide sales of any approved products resulting from the collaboration and will have the opportunity to co-promote in the United States.

AstraZeneca AB Scraps Collaboration Pact with Rigel Pharmaceuticals, Inc. After Arthritis Drug Stalls in Phase III Tests

Rigel Pharmaceuticals, Inc. announced that AstraZeneca AB (AZN) terminated a licensing and collaboration agreement between the companies on RIGL's prospective arthritis drug. Under terms of the February 2010 agreement AZN was responsible for conducting and funding all future development, regulatory filings, manufacturing and global commercialization of products containing RIGL's fostamatinib drug candidate, an oral spleen tyrosine kinase inhibitor. The December 4, 2013, decision follows top-line results released in June from a pair of Phase III trials of fostamatinib after the drug failed to demonstrate a statistically significant difference in modified Total Sharp Score compared with a placebo after 24 weeks. As a result of the termination of the agreement, all rights to fostamatinib revert to RIGL.

POZEN Inc. and AstraZeneca AB Enter into Amendment to Collaboration and License Agreement Regarding Development and Commercialization of Proprietary Fixed Dose Combinations of Proton Pump Inhibitor Esomeprazole Magnesium

On September 16, 2013, POZEN Inc. and AstraZeneca AB entered into Amendment No. 3 to that certain Collaboration and License Agreement, dated as of August 1, 2006, as amended, regarding the development and commercialization of proprietary fixed dose combinations of the proton pump inhibitor (PPI) esomeprazole magnesium with the non-steroidal anti-inflammatory drug (NSAID) naproxen, in a single tablet for the management of pain and inflammation associated with conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID associated gastric ulcers. VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets were co-developed by POZEN and AstraZeneca pursuant to the Agreement and are marketed by AstraZeneca in the United States and numerous other countries. The Amendment makes clarifications to certain intellectual property provisions of the Agreement to clarify that AstraZeneca's rights under those provisions do not extend to products which contain acetyl salicylic acid.

Similar Private Companies By Industry

Company Name Region
Unitech Pharma AB Europe
Pergamum AB Europe
McNeil AB Europe
OxyPharma AB Europe
Laccure AB Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AstraZeneca AB, please visit www.astrazeneca.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.